Drug
Elecoglipron clinical trials
Also written AZD5004 and ECC5004.
- studies test it
- 25
- open now
- 9
- in phase 3
- 9
- first study started
- 2022
Keep track of what changes. Save the elecoglipron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
25 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 8 |
| 2025 | 4 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 2
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 0
AstraZeneca (21) · Eccogene (4)
Often tested with
Tested in the same studies.
Atorvastatin (3) · Rosuvastatin (3) · Dapagliflozin (2) · Mitiglinide (1) · Pioglitazone (1) · Erythromycin (1) · Simvastatin (1) · Repaglinide (1)
Studies
Open first, then newest update. How each study uses elecoglipron is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662213Written as Elecoglipron
- A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMRecruitingPhase 3AstraZenecaNCT07667803Written as Elecoglipron
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07775404Written as Elecoglipron
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFRecruitingPhase 3AstraZenecaNCT07761117Written as Elecoglipron
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.RecruitingPhase 3AstraZenecaNCT07753993Written as Elecoglipron
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinRecruitingPhase 3AstraZenecaNCT07662135Written as Elecoglipron
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662044Written as Elecoglipron
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662109Written as Elecoglipron
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinRecruitingPhase 3AstraZenecaNCT07664553Written as Elecoglipron
- A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive, not recruitingPhase 1AstraZenecaNCT07534592Written as Elecoglipron
- A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT07444424Written as AZD5004
- A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 YearsCompletedPhase 1AstraZenecaNCT07455825Written as AZD5004
- Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.CompletedPhase 2AstraZenecaNCT06579105Written as AZD5004
- A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes MellitusCompletedPhase 1EccogeneNCT06988553Written as AZD5004
- Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityCompletedPhase 2AstraZenecaNCT06579092Written as AZD5004
- Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004CompletedPhase 1AstraZenecaNCT06813781Written as AZD5004
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06948747Written as AZD5004
- A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral FormulationsCompletedPhase 1AstraZenecaNCT06996886Written as AZD5004
- A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004CompletedPhase 1AstraZenecaNCT06742762Written as AZD5004
- A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004CompletedPhase 1AstraZenecaNCT06857695Written as AZD5004 film-coated tablet
See all 25 studies that test elecoglipron →
Given in every arm · 1 — elecoglipron is usual care beside what is tested
Codes
What other systems call elecoglipron · ClinicalTrials.gg INT002209
- MeSH (NLM) C000732067elecoglipronOne source NLM
- UNII (FDA) G94JJ74N5YELECOGLIPRONConfirmed FDA, NLM, Wikidata
- Wikidata Q140528815elecoglipronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C216020ElecoglipronOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732067 | elecoglipron | One source NLM |
| UNII (FDA) | G94JJ74N5Y | ELECOGLIPRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q140528815 | elecoglipron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C216020 | Elecoglipron | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.